Immune-related events in individuals with solid tumors on immunotherapy associate with Th17 and Th2 signatures.
Kao CJ, Charmsaz S, Alden SL, Brancati M, Li HL, Balaji A, Munjal K, Howe K, Mitchell S, Leatherman J, Griffin E, Nakazawa M, Tsai HL, Danilova L, Thoburn C, Gizzi J, Gross NE, Hernandez A, Coyne EM, Shin SM, Babu JS, Apostol GW, Durham J, Christmas BJ, Konig MF, Lipson EJ, Naidoo J, Cappelli LC, Pabani A, Ged Y, Baretti M, Brahmer J, Hoffman-Censits J, Seiwert TY, Garonce-Hediger R, Guha A, Bansal S, Tang L, Jaffee EM, Chandler GS, Mohindra R, Ho WJ, Yarchoan M.
Kao CJ, et al. Among authors: yarchoan m.
J Clin Invest. 2024 Aug 29;134(20):e176567. doi: 10.1172/JCI176567.
J Clin Invest. 2024.
PMID: 39403935
Free PMC article.
Clinical Trial.